Watanabe, S., Yonesaka, K., Tanizaki, J., Nonagase, Y., Takegawa, N., Haratani, K., . . . Nakagawa, K. (2019). Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer. Cancer Med.
シカゴスタイル引用形Watanabe, Satomi, et al. "Targeting of the HER2/HER3 Signaling Axis Overcomes Ligand‐mediated Resistance to Trastuzumab in HER2‐positive Breast Cancer." Cancer Med 2019.
MLA引用形式Watanabe, Satomi, et al. "Targeting of the HER2/HER3 Signaling Axis Overcomes Ligand‐mediated Resistance to Trastuzumab in HER2‐positive Breast Cancer." Cancer Med 2019.
警告: この引用は必ずしも正確ではありません.